Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Annexin Pharmaceuticals ABOSTO:ANNX -2.21%16 3-Year EBITDA Growth Rate is 28.70% as of Jun. 2026, which is 10% above its 10-year median of 26.05. GuruFocus rates OSTO:ANNX with a GF Score™ of 16/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Annexin Pharmaceuticals AB ranks better than 65.39% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 29.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 20.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Annexin Pharmaceuticals AB was 44.50% per year. The lowest was -33.50% per year. And the median was 26.05% per year.
Annexin Pharmaceuticals AB (OSTO:ANNX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Annexin Pharmaceuticals AB 3-Year EBITDA Growth Rate Related Terms
OSTO:ANNX vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Annexin Pharmaceuticals AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexin Pharmaceuticals AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Annexin Pharmaceuticals AB's 3-Year EBITDA Growth Rate falls into.
Annexin Pharmaceuticals AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 28.70% mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a 3-Year EBITDA Growth Rate of 28.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Annexin Pharmaceuticals AB and its competitors. This is 10% above median its historical median of 26.05. According to the industry distribution chart, Annexin Pharmaceuticals AB ranks #390 out of 1127 companies in the Biotechnology industry, placing it in the top 34.6%.
Is Annexin Pharmaceuticals AB's 3-Year EBITDA Growth Rate too high?
Annexin Pharmaceuticals AB's current 3-Year EBITDA Growth Rate of 28.70% is 10% above median its 10-year median of 26.05. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Annexin Pharmaceuticals AB's value of 28.70% is 96.6% above this industry median. Based on the distribution chart, Annexin Pharmaceuticals AB ranks #390 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annexin Pharmaceuticals AB ranks #390 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Annexin Pharmaceuticals AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Annexin Pharmaceuticals AB's value of 28.70% is 96.6% above this benchmark. While the company's 10-year median is 26.05 vs. the industry median of 14.60, Annexin Pharmaceuticals AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annexin Pharmaceuticals AB's current 3-Year EBITDA Growth Rate of 28.70% is 96.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Annexin Pharmaceuticals AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annexin Pharmaceuticals AB's current 3-Year EBITDA Growth Rate is 28.70%, which is 10% above median its own 10-year median of 26.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current 3-Year EBITDA Growth Rate of 28.70%. The current 3-Year EBITDA Growth Rate is 28.70%, which is 10% above median its 10-year median of 26.05 and 96.6% above the Biotechnology industry median of 14.60. Annexin Pharmaceuticals AB's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current 3-Year EBITDA Growth Rate is 28.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
16GF Score
Get the complete analysis for OSTO:ANNX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ANNX has been successfully added to your 
